Deoxycholic acid
- Generic Name
- Deoxycholic acid
- Brand Names
- Belkyra, Kybella
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 83-44-3
- Unique Ingredient Identifier
- 005990WHZZ
- Background
Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.
- Indication
For improvement in appearance of moderate to severe fullness associated with submental fat in adults.
- Associated Therapies
- Submental fat removal therapy
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2010-02-11
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 634
- Registration Number
- NCT00696969
- Locations
- 🇮🇳
Kala-azar medical centre, Muzaffarpur, Bihar, India
🇮🇳Rajendra Memorial research Institute, Patna, Bihar, India
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Banaras Hindu University
- Target Recruit Count
- 400
- Registration Number
- NCT00628719
- Locations
- 🇮🇳
Kala-azar Medical Research Center, Rambag Road, Muzaffarpur, India
Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Kythera Biopharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00618618
- Locations
- 🇬🇧
Investigational Site, Manchester, United Kingdom
Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Kythera Biopharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT00618722
- Locations
- 🇬🇧
Investigational Site, London, United Kingdom
Phase 2 Study for the Treatment of Superficial Lipomas
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Kythera Biopharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00608842
- Locations
- 🇺🇸
David J. Goldberg, M.D., Westwood, New Jersey, United States
🇺🇸Neil S. Sadick, M.D., New York, New York, United States
🇺🇸Gary D. Monheit, M.D., Birmingham, Alabama, United States
Combination Therapy in Indian Visceral Leishmaniasis
- Conditions
- Leishmaniasis, Visceral
- Interventions
- Drug: Liposomal Amphotericin B with MiltefosineDrug: Liposomal Amphotericin B and Paromomycin Sulfate
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Banaras Hindu University
- Target Recruit Count
- 624
- Registration Number
- NCT00523965
- Locations
- 🇮🇳
Kala-azar Medical Research Center, Muzaffarpur, Bihar, India
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Kythera Biopharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00422188
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early
- Conditions
- Aspergillosis
- Interventions
- Behavioral: Galactomannan antigen monitoring, Aspergillus PCROther: blood drawsOther: blood draws for GM monitoringOther: Blood test
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT00361517
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
- Conditions
- Chronic Myeloproliferative DisordersInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Aronex Pharmaceuticals
- Registration Number
- NCT00002742
- Locations
- 🇺🇸
Scott and White Clinic, Temple, Texas, United States
🇺🇸Infections Limited, P.S., Tacoma, Washington, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
- Conditions
- InfectionPulmonary Complications
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 212
- Registration Number
- NCT00003031
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
🇬🇧King's College Hospital, London, England, United Kingdom
🇪🇸Hospital de Cruces, Barakaldo, Bilbao, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.